EX-99.2 6 d896475dex992.htm EX-99.2

Exhibit 99.2

Immatics

Corporate Presentation, March 2020

Forward Looking Statement

This presentation ("Presentation") is for informational purposes only to assist interested parties in making their own evaluation with respect to the proposed business combination (the "Business Combination") between ARYA Sciences Acquisition Corp. ("ARYA") and ImmaticsBiotechnologies GmbH ("Immatics" or the "Company"). The information contained herein does not purport to be all-inclusive and none of ARYA, Immatics and Jefferies LLC nor any of their respective affiliates nor any of its or their control persons, officers, directors, employees or representatives makes any representation or warranty, express or implied, as to the accuracy, completeness or reliability of the information contained in this Presentation. You should consult your own counsel and tax and financial advisors as to legal and related matters concerning the matters described herein, and, by accepting this presentation, you confirm that you are not relying upon the information contained herein to make any decision.

Forward-Looking Statements. Certain statements in this presentation may be considered forward-looking statements. Forward-looking statements generally relate to future events or ARYA's or the Company's future financial or operating performance. For example, statements concerning timing of data read-outs for product candidates, the IND filing for IMA204, IMA301, IMA401, the Company's focus on partnerships to advance its strategy, a two-year projection of use of proceeds and projections of future cash on hand and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may", "should", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by ARYA and its management, and Immatics and its management, as the case may be, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in the section entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in ARYA's Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and other filings with the Securities and Exchange Commission (SEC). Nothing in this presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Neither ARYA nor the Company undertakes any duty to update these forward-looking statements.

Use of Projections. This Presentation contains financial forecasts of the Company. Neither the Company's independent auditors, nor the independent registered public accounting firm of ARYA, audited, reviewed, compiled, or performed any procedures with respect to the projections for the purpose of their inclusion in this Presentation, and accordingly, neither of them expressed an opinion or provided any other form of assurance with respect thereto for the purpose of this Presentation. These projections should not be relied upon as being necessarily indicative of future results.

Additional Information. In connection with the proposed Business Combination, ARYA intends to file with the SEC a registration statement on Form F-4 containing a preliminary proxy statement and a preliminary prospectus of a newly formed company into which ARYA and the Company will combine, and after the registration statement is declared effective, ARYA will mail a definitive proxy statement/prospectus relating to the proposed Business Combination to its shareholders. This Presentation does not contain all the information that should be considered concerning the proposed Business Combination and is not intended to form the basis of any investment decision or any other decision in respect of the Business Combination. ARYA's shareholders and other interested persons are advised to read, when available, the preliminary proxy statement/prospectus and the amendments thereto and the definitive proxy statement/prospectus and other documents filed in connection with the proposed Business Combination, as these materials will contain important information about Immatics, ARYA and the Business Combination. When available, the definitive proxy statement/prospectus and other relevant materials for the proposed Business Combination will be mailed to shareholders of ARYA as of a record date to be established for voting on the proposed Business Combination. Shareholders will also be able to obtain copies of the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus and other documents filed with the SEC, without charge, once available, at the SEC's website at www.sec.gov, or by directing a request to: ARYA Sciences Acquisition Corp., 51 Astor Place, 10th Floor, New York, New York 10003.

Participants in the Solicitation. ARYA and its directors and executive officers may be deemed participants in the solicitation of proxies from ARYA's shareholders with respect to the proposed Business Combination. A list of the names of those directors and executive officers and a description of their interests in ARYA is contained in ARYA's annual report on Form 10-K for the fiscal year ended December 31, 2018, which was filed with the SEC and is available free of charge at the SEC's web site at www.sec.gov, or by directing a request to ARYA Sciences Acquisition Corp., 51 Astor Place, 10th Floor, New York, New York 10003. Additional information regarding the interests of such participants will be contained in the proxy statement/prospectus for the proposed Business Combination when available.

No Offer or Solicitation. This communication is for informational purposes only and does not constitute, or form a part of, an offer to sell or the solicitation of an offer to sell or an offer to buy or the solicitation of an offer to buy any securities, and there shall be no sale of securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law.

Certain information contained in this Presentation relates to or is based on studies, publications, surveys and the Company's own internal estimates and research. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the Company believes its internal research is reliable, such research has not been verified by any independent source. This meeting and any information communicated at this meeting are strictly confidential and should not be discussed outside your organization.

The reader shall not rely upon any statement, representation or warranty made by any other person, firm or corporation (including, without limitation, Jefferies LLC or any of its affiliates or control persons, officers, directors and employees) in making its investment or decision to invest in the Company. None of ARYA nor Jefferies LLC, nor any of their respective affiliates nor any of its or their control persons, officers, directors, employees or representatives, shall be liable to the reader for any information set forth herein or any action taken or not taken by any reader, including any investment in shares of ARYA or the Company.

Key Elements to Build a Global Leader in TCR-based Immunotherapies

True Targets & Right TCRs

- Two technology platforms for the discovery of pHLA targets & T cell receptors
- Foundation to achieve the next advance in immunotherapy, particularly for solid tumors

Proprietary Pipeline of Two Distinct Product Classes: Adoptive Cell Therapies & TCR Bispecifics

- Four ACT product candidates in clinical development covering a broad range of solid cancers
- Next-Generation personalized multi-target therapies designed to achieve durable clinical responses
- Preclinical proof of concept for TCR Bispecifics Lead Candidate with off-the-shelf availability

Sustainable Fundamentals

- Current cash: $125m at YE 2019, no debt
- Strong IP estate & worldwide rights retained on lead programs
- Oncology-focused global leaders as partners validating and expanding our expertise, incl. Amgen, Genmab, BMS, GSK and MD Anderson Cancer Center

Making a Difference – Delivering the Power of T cells to Cancer Patients

Discovering Targets beyond the Cancer Cell Surface to Unlock Immunotherapies for Solid Cancers

CAR-T and Antibody-based Approaches

- CAR-T successful in hematological indications but not in solid cancers
- Major limitation: targeting **surface proteins** on cancer cells, only constituting approx. **25% of the proteome**

The Cancer Proteome

Adapted from Chandran *et al.*, 2019

TCR-based Approaches

- T cell receptors (TCRs) access **intracellular targets** displayed as **peptides** on cell surface through HLA receptors
- **pHLA targets** represent the entire proteome, a **300% increased cancer target space** vs. CAR-T and antibody-based approaches
- Immatics owns **singular technologies** to discover pHLA targets and TCRs to unlock immunotherapies for solid cancers

Proprietary Pipeline of Adoptive Cell Therapy (ACT) & TCR Bispecifics

Developing Novel Treatments Across Two Distinct Product Classes



Recent Major Strategic Partnerships with World-leading Industry Partners

Validation of Immatics' Unique Technologies and Expertise




Immatics – Delivering the Power of T cells to Cancer Patients
immatics
IDENTIFY
True Targets
and Right TCRs
Two Proprietary Technology Platforms
as foundation for the next advance
in immunotherapy,
particularly for solid tumors
XPRESIDENT®
Target Discovery
>200 prioritized targets
XCEPTOR™
TCR Discovery,
Engineering and Validation
DELIVER
Therapeutic Pipelines
of ACT and TCR Bispecifics
Two Distinct Product Classes
building a diverse
pre-clinical and clinical pipeline
Adoptive Cell Therapies
ACTengine® (TCR-T)
ACTallo® (Next-generation)
TCR Bispecifics
TCER™ – Off-the-shelf Biologics with
distinct attributes for use at
an earlier disease stage
PIONEER
Multi-Target Personalized
Precision Immunotherapy
Personalized & Precise
Product candidates against multiple individual
well characterized pHLA targets
Proprietary XPRESIDENT®–AI
for full antigenic profiling and target selection
of any individual tumor
Multi-Target/ TCR
ACTolog® pilot study for multi-target ACT
Building ACTengine® warehouse for
multi-target TCR-T
7

Discovery of True Cancer Targets – XPRESIDENT® Technology Platform

Prioritization of >200 pHLA Targets Covering All Target Classes



Development of the Right TCR – XCEPTOR™ Technology Platform

Pioneering Novel Therapeutic Modalities: T cell Receptors (TCRs) for ACT and Bispecifics



Natural or optimized natural TCR with **micromolar affinity** and favorable **specificity** profile

for genetic engineering of autologous and allogeneic T cells and direct clinical application

Proprietary **XCEPTOR™** Platform TCR Discovery, Engineering and Validation

Fast and efficient discovery of **multiple TCRs per target**

Unique XPRESIDENT®-guided **on- and off-target toxicity screening** to deselect cross-reactive TCRs

Affinity-maturated natural TCR variable domains with **nanomolar affinity** and favorable **specificity** profile

XPRESIDENT®-guided **similar peptide counterselection** during maturation

Highly potent TCR Bispecifics format with **extended half-life** and **antibody-like stability** and manufacturability


Immatics – Delivering the Power of T cells to Cancer Patients
immatics
IDENTIFY
True Targets
and Right TCRs
Two Proprietary Technology Platforms
as foundation for the next advance
in immunotherapy,
particularly for solid tumors
XPRESIDENT®
Target Discovery
>200 prioritized targets
XCEPTOR™
TCR Discovery,
Engineering and Validation
DELIVER
Therapeutic Pipelines
of ACT and TCR Bispecifics
Two Distinct Product Classes
building a diverse
pre-clinical and clinical pipeline
Adoptive Cell Therapies
ACTengine® (TCR-T)
ACTallo® (Next-generation)
TCR Bispecifics
TCER™ – Off-the-shelf Biologics with
distinct attributes for use at
an earlier disease stage
PIONEER
Multi-Target Personalized
Precision Immunotherapy
Personalized & Precise
Product candidates against multiple individual
well characterized pHLA targets
Proprietary XPRESIDENT®–AI
for full antigenic profiling and target selection
of any individual tumor
Multi-Target/ TCR
ACTolog® pilot study for multi-target ACT
Building ACTengine® warehouse for
multi-target TCR-T
10

ACTengine® – Engineered TCR-T Therapy

Autologous, Genetically Modified T cells Expressing a Novel TCR



ACTengine® IMA200 Series	
Approach	• Proprietary TCR • One target/ TCR per trial ➢ Targets from ACTolog® warehouse
Study Design	• 3 First-in-human trials ongoing (IMA201, IMA202, IMA203) • Initial cohort with **dose escalation:** T cell dose increasing from $50x10^6$ to $1,000x10^6$ target-specific T cells/m^2 • N=12-15 patients per trial Expansion cohort upon clinical signal

pHLA Target Characteristics of Immatics' ACT Lead Programs

Comparison of our Frontrunner Targets to Clinically Validated NY-ESO-1

Ongoing clinical ACTengine® trials

	NY-ESO-1[5]	MAGEA4/A8 IMA201	MAGEA1 IMA202	PRAME IMA203	COL6A3 exon 6 IMA204
Naturally presented	Yes[1]	Yes[2]	Yes[2]	Yes[2]	Yes[2]
Specificity class[3]	1	1	1	1	2
Copy number	10-50[4]	100-1,000[2]	50-900[2]	100-1,000[2]	100-700[2]
Tumor types with significant prevalence	Synovial sarcoma (80%) Melanoma (40%) HCC (40%) ...	Sq NSCLC (50%) HNSCC (35%) Bladder carcinoma (30%) Sarcoma Subtypes (up to 80%) ...	HCC (40%) Sq NSCLC (35%) Melanoma (30%) Sarcoma Subtypes (up to 30%) HNSCC (15%) ...	Uterine carcinoma (100%) Melanoma (95%) Ovarian carcinoma (80%) Sq NSCLC (65%) Sarcoma Subtypes (up to 100%) ...	Pancreatic carcinoma (80%) Breast carcinoma (75%) Stomach carcinoma (65%) Sarcoma (65%) NSCLC (55%) Colorectal carcinoma (45%) ...

1 Natural presentation of this peptide has been validated by clinical data, 2 Validated by XPRESIDENT® mass spectrometry. Target peptide copy numbers per cell were determined by AbsQuant™ technology, 3 Internal specificity categorization used at Immatics. Specificity class 1: peptide not routinely found on any normal tissue; no relevant RNA expression detected on critical organs, Specificity class 2: peptide showing a large therapeutic window with rare detections on normal tissue and low RNA expression on critical organs. 4 Purbhoo *et al.*, J Immunol 176:7308-7316 (2006), 5 Robbins *et al.*, J Clin Onco 29(7): 917-924 (2011)

Immatics' clinical frontrunner targets show specificity profiles similar to NY-ESO-1 while having significantly higher peptide copy numbers

ACTengine® – Optimized Manufacturing

Established cGMP Capacities to Advance Next-Generation Cell Manufacturing Developments

Leukapheresis



IMA203: 19-20 days

Manufacturing time (5-6 days)	QC testing (Full sterility, 14 days)

Key plans: Commercial ACTengine® expected 10-11 days

Manufacturing time (5-6 days)	Expedited QC testing (5 days sterility)

Infusion-Ready

Manufacturing for ongoing ACT programs

- ✓ Proprietary short manufacturing process designed to produce phenotypically younger, better persisting T cells
- ✓ T cell products are manufactured at the Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory in collaboration with UTHealth, in **Houston, TX**
- ✓ 1,850 square foot state-of-the-art **cGMP Facility** operated by Immatics personnel
- ✓ Capacity: up to 48 manufacturing runs/month

13

ACTengine® – Encouraging First Patient Responses

Enrollment Status and Exemplary Preliminary Biological Data on First Patients Treated

ACTengine® Studies Enrollment Status

- 22 HLA-A*02:01-positive pts with target-positive biopsy
- Products successfully manufactured for 10/10 patients & **first 4 patients** treated at lowest dose of dose escalation scheme (50 million specific T cells/m²)

Preliminary ACTengine® Data Summary

- Very high frequencies of persisting circulating target-specific T cells observed at lowest infused dose (up to 45%)
- T cell frequencies are comparable to ACTolog® despite approx. 100x lower dose
- Current longest observation period is 12 weeks – during this time T cells persist
- Serial biopsy analysis demonstrates infiltration of target-specific T cells into post-treatment tumor biopsies

Cellular Immunomonitoring in Blood
IMA203 Patient #1



Molecular Immunomonitoring in Blood



Molecular Immunomonitoring in Tumor
IMA202 Patient #2, IMA203 Patient #1



ACTallo® – Next Generation Off-the-shelf TCR-T Therapy

Allogenic, Genetically Modified γδ T cells Expressing a Novel TCR



γδ T cells

- Are **abundant** in the peripheral blood
- Show **intrinsic anti-tumor activity**
- **Naturally infiltrate** solid tumors and correlate with **favorable prognosis**
- Are HLA-independent, thus **do not cause GvHD** in allogenic setting
- Can be **expanded rapidly to high numbers** in a **cGMP-compliant manner**
- Can be effectively redirected using **αβ TCR or CAR constructs**
- **Are very promising for an off-the-shelf cell therapy approach**

ACTallo® T cells effectively kill tumor cells *in vitro*

IMA301 target-positive tumor cells: U20S
(~250 target copies/ cell)



TCER™ – Immatics' TCR Bispecifics

Mode of Action



TCER™ – Engineering an off-the-shelf Biologic



Natural or optimized natural TCR with **micromolar affinity** and favorable **specificity** profile

for genetic engineering of autologous and allogeneic T cells and direct clinical application

Proprietary **XCEPTOR™** Platform TCR Discovery, Engineering and Validation

Fast and efficient discovery of **multiple TCRs per target**

Unique XPRESIDENT®-guided **on- and off-target toxicity screening** to deselect cross-reactive TCRs

Affinity-maturated natural TCR variable domains with **nanomolar affinity** and favorable **specificity** profile

XPRESIDENT®-guided **similar peptide counterselection** during maturation

Highly potent TCR Bispecifics format with **extended half-life** and **antibody-like stability** and manufacturability

17

TCER™ – Summary IMA401 Lead Candidate

Proprietary TCR Bispecifics Format
- TCER™ design confers superior potency and stability compared to multiple alternative bispecific formats
- **Significantly extended half life** as compared to competitor molecules

Very High Potency
- Very low concentration (low pM range) required for in *vitro* killing of tumor cells expressing physiological levels of target pHLA
- **Complete tumor eradication *in vivo*** (tumor xenograft mouse model)

Distinguished Specificity
- Broad therapeutic window (≥ 1,000 – 10,000 fold) as defined by reactivity against tumor cells and healthy tissue cells

Favorable CMC Characteristics
- Excellent manufacturability in CHO cells
- Very stable compound (stress testing in PBS)

Patient Population
- Target-positive solid tumors, including cancers of the lung, head and neck, esophagus, sarcoma and several others

Tumor Xenograft Mouse Model




Immatics – Delivering the Power of T cells to Cancer Patients
immatics
IDENTIFY
True Targets
and Right TCRs
Two Proprietary Technology Platforms
as foundation for the next advance
in immunotherapy,
particularly for solid tumors
XPRESIDENT®
Target Discovery
>200 prioritized targets
XCEPTOR™
TCR Discovery,
Engineering and Validation
DELIVER
Therapeutic Pipelines
of ACT and TCR Bispecifics
Two Distinct Product Classes
building a diverse
pre-clinical and clinical pipeline
Adoptive Cell Therapies
ACTengine® (TCR-T)
ACTallo® (Next-generation)
TCR Bispecifics
TCER™ – Off-the-shelf Biologics with
distinct attributes for use at
an earlier disease stage
PIONEER
Multi-Target Personalized
Precision Immunotherapy
Personalized & Precise
Product candidates against multiple individual
well characterized pHLA targets
Proprietary XPRESIDENT®–AI
for full antigenic profiling and target selection
of any individual tumor
Multi-Target/ TCR
ACTolog® pilot study for multi-target ACT
Building ACTengine® warehouse for
multi-target TCR-T
19

ACTolog® – Pinoneering Personalized Multi-target T cell Therapy

Pilot Trial Using Autologous T cells Expressing Endogenous TCRs



ACTolog® IMA101	
Approach	• Personalized multi-target T cell therapy using a warehouse approach • Autologous T cells, Endogenous TCRs • Clinical proof of concept previously delivered in melanoma by Cassian Yee (MD Anderson Cancer Center) with single target in combination with checkpoint inhibition [Chapuis *et al.*, Sci Transl Med (2013) and Chapuis *et al.*, JCO (2016)]
Indications	• Basket trial in solid tumors
Study Design/ Status	• First-in-human trial ongoing • Cohort 1 (ACTolog® only) • Cohort 2 (plus Atezolizumab) • Total of N=12 patients treated as of January 2020, up to N=20 planned

ACTolog® – Pioneering Personalized Multi-target T cell Therapy

Preliminary Clinical Data as of January 2020

Patients	• 12 patients treated (various solid tumor indications). • Median duration of disease of the patients was 4 years (range 2-18 years) with a median of 6 previous rounds of treatment (range 2-12).
Feasibility	• Very high ACTolog® cell doses (mostly >10^{10}) could be administered. • Patients received mostly multi-target ACTolog® products (range 1-3).
Biological Response	• ACTolog® has led to high target specific T cell levels and persistence with total frequencies up to 80% of all peripheral CD8+ T cells. • T cells exhibit a non-exhausted phenotype. • Target specific T cells were detectable in post-treatment tumor biopsies
Safety Assessment	• ACTolog® IMA101 is well-tolerated to date with no changes to treatment regime required. • The most common adverse events were expected cytopenias associated with the lymphodepleting regimen and Grade 1-2 cytokine release syndrome.
Preliminary Clinical Assessment	• Patients entered the trial with progressive disease, having failed the previous line of therapy. • Median time to progression was ~12 weeks (range 6 weeks to 7 months) by RECIST1.1 (in some cases with transient tumor reduction of up to 26%).

T cell Persistence in Blood



T cell Infiltration into Tumor



Immatics' Multi-target TCR-T Strategy and Vision

Addressing Major Challenges in Immuno-oncology to Make a Therapeutic Difference



The Leadership Team

Experienced Global Leadership Team Across Europe and the US

Harpreet Singh
Chief Executive Officer

Rainer Kramer
Chief Business Officer

Thomas Ulmer
Chief Financial Officer

Steffen Walter
Chief Scientific Officer US

Carsten Reinhardt
Chief Medical Officer

Stephen Eck
Chief Medical Officer US

Toni Weinschenk
Chief Technology Officer

Jordan Silverstein
Head of Strategy

Strong, Focused and Highly Integrated Trans-Atlantic Organization

United to Build a Global Leader in T cell Receptor-based Immunotherapies

Tübingen, Germany, 120 FTEs

Senior Leadership, Research and Development (XPRESIDENT®, XCEPTOR™, TCER™), Translational Development, Clinical Operations, Finance, HR, IT, QM

Munich, Germany, 10 FTEs

Senior Leadership, Business Development, Intellectual Property, Regulatory Affairs, Communications

Houston, Texas , 70 FTEs

Senior Leadership, Research and Development (Adoptive Cell Therapy), CMC, Clinical Operations, Regulatory Affairs, QA/QC, HR, Investor Relations

Continuously Growing IP Portfolio Protecting Proprietary Know-How

Immatics' Patent Estate – Territorial Coverage



- IP protection on >8000 cancer targets, TCRs and technology
- Immatics files patent applications in all major countries and regions
- >220 granted patents in the US
- >15 granted patents in Europe
- > 1500 granted patents overall

- ~ 5000 applications and patents
- >100 patent families

Immatics and ARYA to Merge

Transaction Summary

- Immatics GmbH ("Immatics") and ARYA Sciences Acquisition Corp ("ARYA", Nasdaq: ARYA) to merge pursuant to a business combination agreement to be entered into among Immatics and a newly formed entity formed for the purpose of consummating the transaction
  - Immatics is a clinical-stage biopharmaceutical company that combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors to enable a robust and specific T cell response against these targets.
  - ARYA is a special purpose acquisition company sponsored by Perceptive Advisors
- Expected post transaction equity value of c.$634m, assuming ARYA share price of $10 / share and no redemptions from the ARYA shareholders
- Transaction expected to close in June 2020

Premier Specialist Investor Base

- Provides Immatics with premier investor base and resources to continue executing on its development plan. Key investors of Immatics are currently dievini, AT Impf, Wellington Partners, MIG
- Shareholders of the combined company expected to include current Immatics and ARYA shareholders as well as PIPE from top tier Biotech / Life Sciences investors, including Perceptive

Use of Proceeds

- At time of closing, the combined company is expected to have c.$319m(1) in cash, including proceeds from the c.$104m PIPE financing
  - Funding is expected to primarily be used for clinical programs and technology advancements, including ACTengine®, Next Gen ACT and TCER™ technology
  - Expected to provide runway into 2023

Key Management and Board

- Combined company to be led by Immatics Chief Executive Officer, Harpreet Singh, Ph.D.
- Anticipated directors to include experienced executives from the life sciences sector

1

(1) Net cash after deduction of fees

Terms of Transaction

Pro Forma Valuation and Ownership

Pro Forma Valuation		
Pro Forma Shares Outstanding		63,383,750
Share Price (illustrative)	$	10.00
PF Equity Value	$	633,837,500
Less: PF Cash	$	(318,992,000)
Plus: PF Debt		-
Implied PF Enterprise Value	**$**	**314,845,000**

Sources of Funds [1,3]		
Cash Held in Trust	$	147,842,000
Issuance of Shares	$	350,000,000
Cash on Immatics Balance Sheet	$	90,000,000
PIPE Proceeds	$	104,150,000
Total Sources of Funds	**$**	**691,992,000**

Uses of Funds [1]		
Stock Consideration	$	350,000,000
Fees[2]	$	23,000,000
Remaining Cash (Balance Sheet)[3]	$	318,992,000
Total Uses of Funds	**$**	**691,992,000**

Ownership (thousands of shares) [3,4]

	$10.00	
	Shares	%
ARYA Sponsor (Perceptive)	**6,094**	**9.6%**
Sponsor Shares	*3,594*	*5.7%*
PIPE Participation Shares	*2,500*	*3.9%*
Public Shareholders	14,375	22.7%
SPAC Public Warrant Holders[4]	-	-
Current Immatics Shareholders	35,000	55.2%
PIPE Investor Shares (excl. ARYA Sponsor)	7,915	12.5%
Total	**63,384**	**100.0%**

Use of Proceeds

After Deal Closure the Combined Company is Expected to be well Capitalized

- Approximately $319 million[(1)] of post-transaction cash on the combined company balance sheet to pursue clinical development and platform enhancements
  - Cash runway envisaged for 3+ years

- Projected proceeds will be primarily used for clinical programs and technology advancements in 2020/21:
  - Overall projected spend is estimated $80m[(2)] & $95m in 2020 and 2021
  - R&D programs: $138m[(3)]
  - General corporate purposes: $37m[(3)]
  - Expected cash year end 2021[(1)]: $179m

(1) Projected cash balance including cash held in trust, cash on Immatics' balance sheet, expected PIPE volume of $104m, including transaction costs and ~$35m expenses for 1H/2020; 0% redemption and excluding cash from warrants & exercise of EIP; (2) Thereof ~$35m will occur prior to deal closure in 1H/2020; (3) Partially occurring prior to deal closure.

Milestones to Achieve the Next Advance in Immunotherapy

Immatics' Achievements to Date

- >200 prioritized targets
- Eight proprietary pipeline programs, four of them in clinical development
- ACT: Early clinical data obtained in 2019 with promising biological efficacy
- TCER Bispecifics: Manufacturing activities started for Lead Candidate
- Partnerships with global leaders in the field of immuno-oncology including GSK (2020), BMS (2019), Genmab (2018) & Amgen (2017)

Near-Term Value Inflection Points

Projected major value inflections **2020-2021** are expected to lead to a significant valuation step up

ACTengine®

- Next combined clinical data read-out for IMA201, 202 and 203 trials in 4Q 2020
- IND for IMA204 program

TCER™

- IND for the first TCER™ program IMA401
- Preclinical proof of concept for IMA402

Immatics brings together a breadth of technologies matched with deep knowledge of cancer-specific targets and TCRs to rapidly advance the pipeline of Adoptive Cell Therapy and TCR Bispecifics.

Thank you

www.immatics.com

Please contact us via partnering@immatics.com to learn more about partnering and licensing opportunities utilizing our platform technologies XPRESIDENT®, XCEPTOR™, IMADetect™ and AbsQuant™. 30